ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

A Comparison of the Safety and Efficacy of Sotagliflozin and Baxaglifloxin in the Treatment of Type II Diabetes Mellites. A systemic review and Meta-analysis

Journal: International Research Journal of Pharmacy and Medical Sciences (IRJPMS) (Vol.7, No. 2)

Publication Date:

Authors : ; ;

Page : 50-56

Keywords : ;

Source : Download Find it from : Google Scholarexternal


The effectiveness of Sotagliflozin (200 mg) and Bexagliflozin (20 mg) was evaluated based on HbA1c levels and fasting plasma glucose levels of the participants. Changes in blood pressure and body weight were assessed as secondary outcomes. Regarding safety, adverse events such as genital mycotic infections, urinary tract infections (UTIs), and hypoglycemia were assessed. This meta-analysis showed that Bexagliflozin (20 mg) is more efficient in managing Type 2 Diabetes mellitus than Sotagliflozin (200 mg), in terms of reductions in HbA1c levels, FPG and SBP. This study also showed that the incidence of adverse events was lower with Bexagliflozin. Bexagliflozin showed a greater reduction of HbA1C levels with a mean reduction of -0.63 (-0.65, -0.62); P <0.00001 and Sotagliflozin showed a mean reduction of -0.03 (-0.04, -0.02); P <0.00001. Bexagliflozin showed a mean reduction in FPG of -1.07 (-1.13, -1.02); P <0.00001 while, Sotagliflozin showed a mean reduction of -0.75 (-0.78, -0.72); P <0.00001. Bexagliflozin had a greater mean reduction in the Systolic BP of -2.86 (-3.18, -2.55); P <0.00001, while Sotagliflozin showed a mean reduction of -2.40 (-2.54, -2.27); P <0.00001. Sotagliflozin showed a greater mean reduction in the body weights of -1.67 (-1.73, -1.62); P <0.00001, and Bexagliflozin had a mean reduction of -1.50 (-1.57, -1.43); P <0.00001. Both drugs were seen to be safe when taken orally. Most commonly seen adverse effects in both groups were Hypoglycemia, Genital Mycotic infections and, Urinary Tract Infections. Hypoglycemia was seen almost equally in both Sotagliflozin patients (RR: 1.05 (0.88, 1.26)) and Bexagliflozin (RR: 0.98 (0.73, 1.33)). Sotagliflozin increased the risk of genital mycotic infection – (RR: 2.14 (0.48, 9.50)) in contrast to Bexagliflozin - RR: 0.46 (0.09, 2.32). Bexagliflozin was found to predispose the patients to UTIs (RR: 2.88 (1.41, 5.86)) in contrast to Sotagliflozin with RR: 0.97 (0.70, 1.34).

Last modified: 2024-04-23 15:31:15